207.64
price down icon0.48%   -1.0734
 
loading
前日終値:
$208.71
開ける:
$207.95
24時間の取引高:
215.70K
Relative Volume:
0.47
時価総額:
$12.79B
収益:
$393.98M
当期純損益:
$-367.45M
株価収益率:
-32.99
EPS:
-6.293
ネットキャッシュフロー:
$-460.07M
1週間 パフォーマンス:
-1.16%
1か月 パフォーマンス:
+6.72%
6か月 パフォーマンス:
+34.94%
1年 パフォーマンス:
+63.16%
1日の値動き範囲:
Value
$206.02
$212.48
1週間の範囲:
Value
$205.40
$216.45
52週間の値動き範囲:
Value
$118.03
$216.45

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
名前
Ascendis Pharma A S Adr
Name
セクター
Healthcare (1146)
Name
電話
-
Name
住所
-
Name
職員
1,017
Name
Twitter
Name
次回の収益日
2024-12-13
Name
最新のSEC提出書
Name
ASND's Discussions on Twitter

ASND を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ASND
Ascendis Pharma A S Adr
207.55 12.64B 393.98M -367.45M -460.07M -6.293
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
409.81 105.69B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
475.59 61.52B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.71 60.69B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
816.50 50.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
316.14 35.25B 4.56B -176.77M 225.30M -1.7177

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-03 再開されました Morgan Stanley Overweight
2025-05-05 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-04-16 開始されました RBC Capital Mkts Outperform
2025-01-07 開始されました UBS Buy
2024-09-05 アップグレード Oppenheimer Perform → Outperform
2024-06-25 アップグレード TD Cowen Hold → Buy
2024-05-31 開始されました Stifel Buy
2023-12-20 開始されました Jefferies Buy
2023-06-14 再開されました Credit Suisse Neutral
2023-04-05 ダウングレード Oppenheimer Outperform → Perform
2023-04-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-04-03 ダウングレード Credit Suisse Outperform → Neutral
2022-10-20 開始されました Goldman Buy
2022-08-30 再開されました Berenberg Buy
2022-03-28 再開されました Wedbush Outperform
2022-03-15 アップグレード BofA Securities Neutral → Buy
2022-03-01 開始されました Citigroup Buy
2022-02-14 アップグレード Oppenheimer Perform → Outperform
2022-01-06 開始されました Cowen Market Perform
2021-12-08 開始されました Wells Fargo Overweight
2021-10-20 ダウングレード BofA Securities Buy → Neutral
2021-03-30 ダウングレード Oppenheimer Outperform → Perform
2021-03-11 再開されました Stifel Buy
2020-12-17 開始されました Berenberg Buy
2020-09-14 再開されました JP Morgan Overweight
2020-03-20 開始されました Oppenheimer Outperform
2019-10-11 開始されました Morgan Stanley Overweight
2019-03-25 開始されました Evercore ISI Outperform
2019-01-24 開始されました Cantor Fitzgerald Overweight
2019-01-24 アップグレード Leerink Partners Mkt Perform → Outperform
2018-06-26 開始されました Stifel Buy
2018-04-02 繰り返されました Leerink Partners Mkt Perform
2017-05-11 開始されました JP Morgan Overweight
2017-03-09 ダウングレード Leerink Partners Outperform → Mkt Perform
2017-02-09 開始されました Credit Suisse Outperform
2016-09-26 開始されました Wedbush Outperform
すべてを表示

Ascendis Pharma A S Adr (ASND) 最新ニュース

pulisher
Oct 13, 2025

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 13, 2025
pulisher
Oct 10, 2025

Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm

Oct 10, 2025
pulisher
Oct 08, 2025

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm

Oct 08, 2025
pulisher
Oct 03, 2025

Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm

Oct 03, 2025
pulisher
Aug 20, 2025

Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com

Aug 20, 2025
pulisher
Aug 11, 2025

Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl

Aug 11, 2025
pulisher
Aug 08, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 08, 2025
pulisher
Aug 08, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily

Aug 08, 2025
pulisher
Aug 07, 2025

Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com

Aug 07, 2025
pulisher
Aug 04, 2025

Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com

Aug 04, 2025
pulisher
Jul 31, 2025

Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily

Jul 31, 2025
pulisher
Jul 29, 2025

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail

Jul 29, 2025
pulisher
Jul 28, 2025

Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com

Jul 28, 2025
pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl

Jul 25, 2025
pulisher
Jul 14, 2025

Ascendis Pharma reports positive results from hypothyroid trial - MSN

Jul 14, 2025
pulisher
Jul 02, 2025

Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com

Jul 02, 2025
pulisher
Jun 30, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 30, 2025
pulisher
Jun 26, 2025

European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize

Jun 26, 2025
pulisher
Jun 10, 2025

Canaccord holds Ascendis Pharma stock at $84 target - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

BofA raises Ascendis Pharma stock target to $216 - Investing.com

Jun 09, 2025
pulisher
Jun 04, 2025

Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN

Jun 04, 2025
pulisher
Jun 03, 2025

Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl

Jun 03, 2025
pulisher
Jun 02, 2025

BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

European ADRs Climb With Biotech Stocks Leading The Charge - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com

Jun 02, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com

May 27, 2025
pulisher
May 25, 2025

Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India

May 25, 2025
pulisher
May 15, 2025

Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India

May 15, 2025
pulisher
May 14, 2025

Ascendis Pharma grants new employee warrants - Investing.com

May 14, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial - Investing.com

May 13, 2025
pulisher
May 12, 2025

Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 09, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 09, 2025
pulisher
May 08, 2025

In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX

May 08, 2025
pulisher
May 02, 2025

Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com

May 02, 2025
pulisher
May 02, 2025

Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 16, 2025

RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com

Apr 16, 2025
pulisher
Apr 15, 2025

Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl

Apr 15, 2025
pulisher
Apr 14, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 11, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 07, 2025

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView

Apr 07, 2025
pulisher
Mar 27, 2025

UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com

Mar 27, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 17, 2025

Rising Momentum: Is Ascendis Pharma a Hidden Gem? - StocksToTrade

Mar 17, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025

Ascendis Pharma A S Adr (ASND) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.84
price up icon 5.01%
$88.10
price up icon 2.50%
$32.70
price down icon 0.11%
$103.63
price up icon 1.00%
$163.80
price up icon 1.47%
biotechnology ONC
$316.39
price down icon 1.30%
大文字化:     |  ボリューム (24 時間):